title: [Attenuation of inhibitory influence of hormones on adenylyl cyclase systems in the myocardium and brain of rats with obesity and type 2 diabetes mellitus and effect of intranasal insulin on it].
abstract: The functional state of the adenylyl cyclase signaling system (ACSS) and its regulation by hormones, the inhibitors of adenylyl cyclase (AC)--somatostatin (SST) in the brain and myocardium and 5-nonyloxytryptamine (5-NOT) in the brain of rats of different ages (5- and 7-month-old) with experimental obesity and a combination of obesity and type 2 diabetes mellitus (DM2), and the effect of long-term treatment of animals with intranasally administered insulin (II) on ACSS were studied. It was shown that the basal AC activity in rats with obesity and DM2 was increased in the myocardium, and to the lesser extent in the brain, the treatment with II reducing this parameter. The AC stimulating effects of forskolin are decreased in the myocardium, but not in the brain, of rats with obesity and DM2. The treatment with II restored the AC action of forskolin in the 7-month-old animals, but has little effect on it in the 5-month-old rats. In obesity the basal AC activity and its stimulation by forskolin varied insignificantly and weakly changed in treatment of animals with II. The AC inhibitory effects of SST and 5-NOT in the investigated pathology are essentially attenuated, the effect of SST to the greatest extent, which we believe to be associated with a reduction in the functional activity of Gi-proteins. The II treatment of animals with obesity and with a combination of obesity and DM2 restored completely or partially the AC inhibiting effects of hormones, to the greatest extent in the brain. Since impaired functioning of ACSS is one of the causes of the metabolic syndrome and DM2, their elimination by treatments with II can be an effective approach to treat these diseases and their CNS and cardiovascular system complications.
authors: L A
authors: LA
authors: Kuznetsova
authors: S A
authors: SA
authors: Plesneva
authors: T S
authors: TS
authors: Sharova
authors: M N
authors: MN
authors: Pertseva
authors: A O
authors: AO
authors: Shpakov
mesh_terms: D000067956:Adenylyl Cyclase Inhibitors; D000262:Adenylyl Cyclases / Q000378:metabolism*; D000281:Administration, Intranasal; D000818:Animals; D001921:Brain / Q000187:drug effects / Q000254:growth & development / Q000378:metabolism*; D002316:Cardiotonic Agents / Q000494:pharmacology; D005576:Colforsin / Q000494:pharmacology; D003924:Diabetes Mellitus, Type 2 / Q000378:metabolism*; D006321:Heart / Q000187:drug effects / Q000254:growth & development; D007328:Insulin / Q000008:administration & dosage / Q000494:pharmacology*; D009206:Myocardium / Q000378:metabolism*; D009765:Obesity / Q000378:metabolism*; D051381:Rats; D017208:Rats, Wistar; D013004:Somatostatin / Q000494:pharmacology*; D014363:Tryptamines / Q000494:pharmacology
chemical_list: D000067956:Adenylyl Cyclase Inhibitors; D002316:Cardiotonic Agents; D007328:Insulin; D014363:Tryptamines; C089008:5-(nonyloxy)tryptamine; D005576:Colforsin; D013004:Somatostatin; D000262:Adenylyl Cyclases